Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers
Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers
复制标题
DOI：
10.1016/j.drugalcdep.2016.11.030
复制
发表时间：
2017-03-01
影响因子：
4.2
通讯作者：
Walsh, Sharon L.
中科院分区：
文献类型：
--
作者：
Babalonis, Shanna;Haney, Margaret;Walsh, Sharon L.
背景：大麻二酚（CBD）是大麻植物的天然成分。在过去的几年中，人们对分离的 CBD 的治疗效果产生了极大的兴趣，目前正在探索它对多种疾病（例如疼痛、癫痫、癌症、各种药物依赖性）的治疗作用。然而，CBD 仍然是美国管制物质法案 (CSA) 中的附表 I 药物。尽管有其现状，但尚无关于其滥用倾向的良好控制数据。 方法：健康、经常吸食大麻的人 (n = 31) 参加了这项随机、安慰剂对照、双盲、多中心研究，单独口服大麻二酚 (0、200、400、800 毫克)，并与吸食大麻 (0.01%、5.3-5.8% THC) 联合用药。参与者在 8 次每周一次的门诊（7.5 小时）中接受一种剂量组合。关于药物相互作用效应的主要发现之前已有报道（Haney 等人，2016）。本研究是对数据的二次分析，旨在检查口服大麻二酚（200、400、800 毫克）与口服安慰剂和活性吸食大麻（5.3-5.8% THC）相比的滥用倾向。结果：活性大麻确实产生了与滥用相关的主观效应（例如，高）（p < 0.05）。然而，CBD 在收集的所有指标上都与安慰剂相似（p > 0.05）。结论：总体而言，CBD 在测试剂量下没有显示出任何滥用倾向的信号，这些数据可能有助于美国关于 CSA 上 CBD 时间表的监管决策。 (C) 2016 Elsevier Ireland Ltd. 保留所有权利。
Background: Cannabidiol (CBD) is a naturally occurring constituent of the marijuana plant. In the past few years, there has been great interest in the therapeutic effects of isolated CBD and it is currently being explored for numerous disease conditions (e.g., pain, epilepsy, cancer, various drug dependencies). However, CBD remains a Schedule I drug on the U.S. Controlled Substances Act (CSA). Despite its status, there are no well-controlled data available regarding its abuse liability.Methods: Healthy, frequent marijuana users (n = 31) were enrolled in this within subject, randomized, placebo-controlled, double-blind, multisite study that administered oral cannabidiol (0, 200, 400, 800 mg) alone and in combination with smoked marijuana (0.01%, 5.3-5.8% THC). Participants received one dose combination across 8 once-weekly outpatient sessions (7.5 h). The primary findings on the drug interaction effects were previously reported (Haney et al., 2016). The present study is a secondary analysis of the data to examine the abuse liability profile of oral cannabidiol (200, 400, 800 mg) in comparison to oral placebo and active smoked marijuana (5.3-5.8% THC).Results: Active marijuana reliably produced abuse-related subjective effects (e.g., high) (p < 0.05). However, CBD was placebo-like on all measures collected (p > 0.05).Conclusions: Overall, CBD did not display any signals of abuse liability at the doses tested and these data may help inform U.S. regulatory decisions regarding CBD schedule on the CSA. (C) 2016 Elsevier Ireland Ltd. All rights reserved.